BioWorld Science

Sep. 10, 2012

View Archived Issues

New ESC guidelines recommend use of ticagrelor

Read More

Symphogen licenses Sym-004 to Merck KGaA

Read More

FDA continues review of crofelemer NDA beyond PDUFA date

Read More

ValiRx reports data on VAL-201 for breast cancer

Read More

Novel HDAC inhibitors prepared at Dana Farber Cancer Institute

Read More

CSIR patents novel agents for cancer

Read More

Glenmark Pharmaceuticals prepares new MPGES-1 inhibitors

Read More

Novel DGAT1 inhibitors synthesized by Merck & Co.

Read More

Scientists at BioRelix present new flavin derivatives

Read More

Phase II zabofloxacin results presented at ICAAC

Read More

Generon begins clinical studies of IL-22 product

Read More

FG-3019 safe and well tolerated in phase II study in IPF

Read More

Aileron Therapeutics reports on new therapeutic drug program

Read More

NeurOp receives NIH funding for ischemia research

Read More

PM-01183 receives positive opinion for orphan drug status in E.U.

Read More

Sanofi develops new 11-beta-HSD1 inhibitors for the treatment of diabetes

Read More

InSite Vision completes enrollment of DOUBle study

Read More

Janssen makes submissions to the FDA for two different Xarelto sNDAs

Read More

SFJ and Pfizer sign agreement to codevelop treatment for advanced NSCLC

Read More

Atu-111 shows efficacy in preclinical model of acute lung injury

Read More

Phase I/II trial of Astex's HSP 90 inhibitor begins

Read More

Cedars-Sinai Heart Institute receives funding to further study cardiac stem cells

Read More

AstraZeneca discontinues development of candidate in obesity collaboration with Palatin

Read More

Actinium to begin screening patients for second cohort of phase I/II trial in AML

Read More